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CASE REPORT
TREATMENT OF SEVERE CHROMOBLASTOMYCOSIS WITH ITRACONAZOLE  
AND 5-FLUCYTOSINE ASSOCIATION
Vicente Sperb ANTONELLO(1), Marcelo Campos APPEL DA SILVA(2), Eduardo CAMBRUZZI(3), Dimas Alexandre KLIEMANN(1), 
Breno Riegel SANTOS(1) & Flávio QUEIROZ-TELLES(4)
SUMMARY
Chromoblastomycosis is a chronic human melanized fungi infection of the subcutaneous tissue caused by traumatic inoculation 
of a specific group of dematiaceous fungi through the skin, often found in barefooted agricultural workers, in tropical and subtropical 
climate countries. We report the case of a male patient presenting a slow-growing pruriginous lesion on the limbs for 20 years, 
mistreated over that time, which was diagnosed and successfully treated as chromoblastomycosis. Besides the prevalence of this 
disease, treatment is still a clinical challenge. 
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INTRODUCTION
Chromoblastomycosis (CBM) is a chronic human melanized fungi 
infection of subcutaneous tissue caused by traumatic inoculation of a 
specific group of dematiaceous fungi (usually Fonsecaea pedrosoi or 
Cladophialophora carrionii) through the skin1,14. It has been described 
worldwide, but it is most commonly seen in tropical or subtropical 
climates18. It may be encountered as an occupational-related disease, 
mainly in male barefooted-agricultural workers21.
Differential diagnoses may include infectious diseases, such as 
blastomycosis, paracoccidioidomycosis, leishmaniasis and verrucose 
tuberculosis, and non-infectious disorders, as sarcoidosis and 
psoriasis13,18. We report a patient from the state of Rio Grande do Sul 
with CBM diagnosed by histology, and who responded successfully 
to oral itraconazole (ITZ) and 5-flucytosine (5-FC) combined therapy.
CASE REPORT
A 55-year-old male agricultural worker presented with a 20-year-old, 
slow-growing, pruriginous and erythematous plaque with well-defined 
borders and covered by “black dots”, extending from the left ankle to 
the left mid thigh (Fig. 1-A). His medical history was remarkable only 
for the diagnosis of insulin-dependent diabetes mellitus since he was 
40 years old. Several ointments had been used to treat the condition, 
as well as oral ITZ, fluconazole (FCZ) and terbinafine (TBF), with no 
major improvement. No fungal growth was obtained after culture of 
biopsy specimens. Melanized fungi cells were seen in hematoxylin and 
eosin tissue sections as shown in Fig. 1-B. Clinical and histological 
findings were compatible with the diagnosis of severe CBM, with 
presence of clustered muriform cells. The disease severity, according 
to QUEIROZ-TELLES et al. score was severe18. Treatment with oral 
ITZ 400 mg daily and 5-FC 2 grams q.i.d. was initiated. Within two 
months, dramatic clinical improvement was observed, and by the end of 
12 months complete clinical healing of the lesion was achieved (Fig. 2). 
Follow-up of the laboratorial exams were performed every three months 
and included blood cell count, creatinine and liver function panels, and 
showed no alterations until the last consultation (Table 1). 
DISCUSSION
CBM is a therapeutic challenge for which there is no treatment of 
choice. Several drug options are suggested, based on reports of non-
comparative studies and case series, rather than randomized controlled 
trials7,11,18. Treatment may depend on the etiological agent, size and extent 
of the lesions, the patient’s individual tolerance, status of the immune 
system and economic features11, but is often associated with low cure 
rates and high relapse rates18. Besides that, clinical, mycological and 
histopathological data can be used to guide appropriate antifungal drug 
choice.
Small lesions in the early stages can be treated with surgical resection 
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with curettage and desiccation. Treatments with carbon dioxide laser, 
cryotherapy and topical heat also have been reported10,11,18. However, 
recurrences are common. Moderate and severe forms, with widespread 
lesions, usually require systemic treatment. While amphotericin B, 
thiabendazole, 5-FC and ketoconazole are variably effective in this 
condition, ITZ and TBF demonstrated the best results at high doses for 
6-12 months1,7,14,21. However, a cure is difficult to achieve, and prolonged 
remission is an acceptable outcome. Given the high relapse rate of the 
disease, therapeutic combinations may increase the cure rate18. In our 
patient, systemic antifungal treatment with ITZ associated with 5-FC 
was used for 12 months with excellent response.
Due to the lack of new antifungal compounds, in the 1970s the 
combination of antifungal drugs was considered for treatment of 
subcutaneous mycoses. 5-FC - a pyrimidine derivative, with main action 
in inhibiting the synthesis of nucleic acids of the fungal cells, active in 
vitro and in vivo against yeasts (Candida albicans and Cryptococcus 
neoformans, Aspergillus sp. and dematiaceous fungi)3,17,23 - was the only 
drug that had no activity directly to the fungal membrane and that could 
be combined with other antifungal substances5,15,16,20.
Based on the additive effect observed in vitro, BOPP introduced 
in 1976 the combination of intravenous amphotericin B with 5-FC in 
the treatment of CBM8. This combination proved to be advantageous 
Fig. 1 - A. Erythematous plaque with well-defined borders and covered by “black dots”; B. Melanized fungi cells in hematoxilin-eosin tissue sections.
Fig. 2 - Complete clinical healing of the lesion after 12 months of treatment with Itraconazole 
and 5-flucytosine.
Table 1 
Laboratorial exams of the chromoblastomycosis patient 
Exams\Date 08/28/09 10/19/09 12/17/09 04/06/10 06/18/10 10/04/10
RBC* 4,79 mil 4,74 mil 4,84 mil 4,92 mil 4,75 mil 5,22 mil
Hb** 12,5 13,3 13,6 13,7 13,3 13,9
Leucocytes 8550 6350 7180 8070 8170 10330
Creatinine 1,06 1,12 1,2 1,19 1,11 1,07
TGP 12 23 18 17 14 19
TGO 13 17 20 19 20 18
*RBC = Red blood cells; **Hb = Hemoglobin.
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over monotherapy with 5-FC12. However, the related nephrotoxicity 
of amphotericin B and prolonged period of hospitalization for drug 
administration have motivated the search for less toxic regimens. The 
association of two oral compounds, 5-FC and thiabendazole, was tried 
with enthusiastic results2,22.
The combination of ITZ and 5-FC, although assessed in a small 
number of patients, was very effective even in severe forms of 
subcutaneous mycoses6,9,19. Pharmacological data on antifungal drugs 
demonstrated an additive effect against fungi - where 5-FC acts by causing 
suppression of the yeast’s DNA synthesis and ITZ acting on the fungi´s 
cytoplasmatic membrane - by inhibiting the synthesis of ergosterol, an 
important substance for fungal growth4. Despite an insufficient number 
of cases to compose a detailed comparison, the combined therapy of ITZ 
and 5-FC may be an excellent option for severe or unresponsive cases of 
CBM after monotherapy with ITZ or terbinafine. Due to the difficulty in 
acquiring 5-FC in Brazil at present, the accomplishment of a comparative 
study involving a larger number of patients is missing.
Finally, it is important to consider that treatment success depends also 
on an early diagnosis and the choice of the appropriate antifungal agent.
RESUMO
Tratamento de cromoblastomicose severa com a associação 
itraconazole e 5-flucitosina
Cromoblastomicose é uma infecção fúngica crônica do tecido 
subcutâneo causada pela inoculação traumática de um grupo específico 
de fungos através da pele, encontrados eventualmente em trabalhadores 
do campo descalços em países de clima tropical e subtropical. 
Relatamos aqui o caso de um paciente do sexo masculino com uma 
lesão dermatológica de crescimento lento e pruriginosa nos membros 
inferiores por 20 anos, diagnosticada e tratada com sucesso para 
cromoblastomicose. Apesar da prevalência desta doença em nossa região, 
o tratamento ainda é um desafio.
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